Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Eureka's InvisiMask human antibody nasal spray offers protection against SARS-CoV-2 in mice

Eureka Therapeutics, Inc. announced today successful preclinical results from its InvisiMask™ Human Antibody Nasal Spray in mice, which offers protection against SARS-CoV-2 S pseudotyped virus infection for up to 10 hours.

14 Dec 2020

New analysis method could pave the way for important breakthroughs in immunotherapy

In a new study, researchers at Uppsala University have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphatic leukemia. This has awakened hopes that this analysis method could pave the way for important breakthroughs in immunotherapy research and treatment.

11 Dec 2020

Rapid lateral flow immunoassay enables fluorescence detection of SARS-Cov-2 RNA

The COVID-19 pandemic has highlighted the need for rapid and accurate nucleic acid detection at the point of care. To meet this need, scientists from the Suzhou Institute of Biomedical Engineering and Technology have developed a novel amplification-free rapid SARS-CoV-2 nucleic acid detection platform based on hybrid capture fluorescence immunoassay (HC-FIA).

11 Dec 2020

Osteoporosis drug also promotes infiltration of immune cells in breast tumors

The team of Eva González-Suarez, from the CNIO and IDIBELL, and the team of Christos Sotiriou, from the Jules Bordet Institute, demonstrate that a drug already used to treat osteoporosis promotes the infiltration of immune cells in breast tumors.

10 Dec 2020

MUSC cancer researcher named as a 2020 fellow of National Academy of Innovators

In recognition of her spirit of innovation and the lasting impact of her work on cancer patients, MUSC Hollings Cancer Center researcher Nancy Klauber-DeMore, M.D., has been named as a 2020 fellow of the National Academy of Innovators, the organization announced Dec. 8.

10 Dec 2020

Researchers analyze outcomes in patients with primary central nervous system lymphoma

Primary central nervous system lymphoma (PCNSL) is a type of cancer that develops in the brain and or spinal cord.

7 Dec 2020

Chemotherapy combined with blinatumomab increases survival for patients with Ph-negative B-ALL

A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative B-cell ALL (Ph-negative B-ALL).

7 Dec 2020

STE90-C11, a SARS-CoV-2 neutralizing antibody, shows high inhibition of RBD-ACE2 binding

In a new study, researchers describe the identification of a neutralizing antibody that binds to the RBD at the same site as the human host cell receptor.

7 Dec 2020

Secukinumab for treatment of plaque psoriasis in children: Added benefit not proven

The monoclonal antibody secukinumab is approved for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of six years who are candidates for systemic therapy.

5 Dec 2020

Good cholesterol helps SARS-CoV-2 enter cells

The researchers explained that the SARS-CoV-2 can infect human host cells after its viral spike protein (SARS-2-S) binds to a cellular surface receptor called the angiotensin-converting enzyme 2 (ACE2).

30 Nov 2020

A mutant SARS-CoV-2 subspecies from minks may evade antibody detection

In a recent research letter published on the bioRxiv preprint server, scientists from Japan discovered that the mutation of spike glycoprotein in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) derived from farmed minks can also be found in the group of individuals with coronavirus disease (COVID-19) and subsequently evade detection by our immune system.

30 Nov 2020

Monoclonal antibody HB27 shows potent neutralizing activity against SARS-CoV-2

A new study reports a very promising anti-SARS-CoV-2 monoclonal antibody, HB27, that appears to have two distinct mechanisms of action inhibiting the virus-host cell interaction and subsequent infection.

27 Nov 2020

Inhibiting SARS-CoV-2 cell entry with monoclonal antibodies against staphylococcal enterotoxin B superantigen

In a recent cutting-edge study, US researchers unveiled an anti-staphylococcal enterotoxin B monoclonal antibody that can be repurposed to target the cleavage site of the SARS-CoV-2 spike glycoprotein and, in turn, inhibit viral infection. Their findings are currently available on bioRxiv preprint server.

25 Nov 2020

New drug treatment could soon benefit people with rheumatoid arthritis

People with Rheumatoid Arthritis (RA) could soon benefit from a new drug treatment that not only suppresses inflammation but also significantly reduces patient reported pain scores. Otilimab is a monoclonal antibody, biologic drug, which targets and suppresses the inflammatory cytokine GM-CSF.

25 Nov 2020

SARS-CoV-2 spike deletion mutations may evade current vaccine candidates, study finds

A thought-provoking new study reports that the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antibodies elicited by natural infection may not be able to neutralize emerging strains that display deletion mutations in their genomic RNA.

23 Nov 2020

Researchers develop recombinant SARS-CoV-2 model to aid vaccine and antiviral research

Researchers have developed a fluorescent reporter gene-bearing recombinant form of SARS-CoV-2, which is capable of replication.

23 Nov 2020

FDA schedules meeting to discuss emergency use authorization of COVID-19 vaccine from Pfizer

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19.

23 Nov 2020

Monoclonal Antibody News and Research

Further Reading

Eureka's InvisiMask human antibody nasal spray offers protection against SARS-CoV-2 in mice

New analysis method could pave the way for important breakthroughs in immunotherapy

Rapid lateral flow immunoassay enables fluorescence detection of SARS-Cov-2 RNA

Osteoporosis drug also promotes infiltration of immune cells in breast tumors

MUSC cancer researcher named as a 2020 fellow of National Academy of Innovators

Researchers analyze outcomes in patients with primary central nervous system lymphoma

Chemotherapy combined with blinatumomab increases survival for patients with Ph-negative B-ALL

STE90-C11, a SARS-CoV-2 neutralizing antibody, shows high inhibition of RBD-ACE2 binding

Secukinumab for treatment of plaque psoriasis in children: Added benefit not proven

Good cholesterol helps SARS-CoV-2 enter cells

A mutant SARS-CoV-2 subspecies from minks may evade antibody detection

Monoclonal antibody HB27 shows potent neutralizing activity against SARS-CoV-2

Inhibiting SARS-CoV-2 cell entry with monoclonal antibodies against staphylococcal enterotoxin B superantigen

New drug treatment could soon benefit people with rheumatoid arthritis

SARS-CoV-2 spike deletion mutations may evade current vaccine candidates, study finds

Researchers develop recombinant SARS-CoV-2 model to aid vaccine and antiviral research

FDA schedules meeting to discuss emergency use authorization of COVID-19 vaccine from Pfizer

Anti-SARS-CoV-2 hyperimmune globulin produced from convalescent plasma pool has 3-fold antibody neutralizing activity

Genetic modification in ‘coat’ of fatal brain virus may allow it to escape antibodies

New understanding of glycan signatures of the SARS-COV-2 S1 spike protein

Antibodies eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®